Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Weaver Consulting Group

Weaver Consulting Group decreased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 1.2% in the fourth quarter, HoldingsChannel reports. The firm owned 46,935 shares of the medical research company’s stock after selling 558 shares during the quarter. Edwards Lifesciences accounts for 1.1% of Weaver Consulting Group’s portfolio, making the stock its 23rd biggest position. Weaver Consulting Group’s holdings in Edwards Lifesciences were worth $3,475,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Purus Wealth Management LLC boosted its stake in shares of Edwards Lifesciences by 5.2% in the second quarter. Purus Wealth Management LLC now owns 3,212 shares of the medical research company’s stock worth $297,000 after buying an additional 160 shares during the last quarter. JFS Wealth Advisors LLC lifted its holdings in Edwards Lifesciences by 31.1% in the third quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 166 shares during the period. Seascape Capital Management boosted its position in Edwards Lifesciences by 0.5% in the 3rd quarter. Seascape Capital Management now owns 32,989 shares of the medical research company’s stock worth $2,177,000 after purchasing an additional 174 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. boosted its position in Edwards Lifesciences by 1.2% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 15,341 shares of the medical research company’s stock worth $1,417,000 after purchasing an additional 184 shares in the last quarter. Finally, Martin Capital Advisors LLP grew its stake in shares of Edwards Lifesciences by 0.7% during the 3rd quarter. Martin Capital Advisors LLP now owns 25,546 shares of the medical research company’s stock worth $1,686,000 after purchasing an additional 186 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of several analyst reports. Barclays boosted their target price on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company an “overweight” rating in a research note on Monday, December 2nd. Citigroup upped their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Evercore ISI dropped their target price on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. JPMorgan Chase & Co. upped their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a “neutral” rating in a report on Friday, October 25th. Finally, Robert W. Baird lowered their price target on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating on the stock in a research report on Friday, October 25th. Sixteen investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $79.40.

Insider Buying and Selling

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $69.51, for a total transaction of $347,550.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,262,521.36. This represents a 9.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 37,500 shares of company stock worth $2,508,350. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Price Performance

EW stock opened at $73.76 on Wednesday. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a market capitalization of $43.50 billion, a PE ratio of 10.64, a price-to-earnings-growth ratio of 3.63 and a beta of 1.11. The business has a 50 day simple moving average of $71.26 and a 200-day simple moving average of $72.28.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.57 billion. During the same period in the prior year, the business earned $0.59 EPS. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.56 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.